Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States

BACKGROUND: Monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are a promising treatment for limiting the progression of coronavirus disease 2019 (COVID-19) and decreasing strain on hospitals. Their use, however, remains limited, particularly in disadva...

Descripción completa

Detalles Bibliográficos
Autores principales: Rainwater-Lovett, Kaitlin, Redd, John T, Stewart, Miles A, Calles, Natalia Elías, Cluff, Tyler, Fang, Mike, Panaggio, Mark J, Lambrou, Anastasia S, Thornhill, Jonathan K, Bradburne, Christopher, Imbriale, Samuel, Freeman, Jeffrey D, Anderson, Michael, Kadlec, Robert P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364980/
https://www.ncbi.nlm.nih.gov/pubmed/34409125
http://dx.doi.org/10.1093/ofid/ofab398

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364980/
https://www.ncbi.nlm.nih.gov/pubmed/34409125
http://dx.doi.org/10.1093/ofid/ofab398

Ejemplares similares